| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802643801048 | 264380104 | VESICARE F.C.TAB 5MG/TAB BTx30 (3BL x10) | 15.37 | 16.12 | 22.22 |
| 05/2018 | 2802643802045 | 264380204 | VESICARE F.C.TAB 10MG/TAB BTx 30 (3BL x 10) | 17.10 | 17.94 | 24.72 |
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Solifenacin is a competitive muscarinic acetylcholine receptor antagonist. The binding of acetylcholine to these receptors, particularly the M3 receptor subtype, plays a critical role in the contraction of smooth muscle. By preventing the binding of acetylcholine to these receptors, solifenacin reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine and reducing the number of incontinence episodes.
Overdosage with solifenacin can potentially result in severe anticholinergic effects and should be treated accordingly. The highest solifenacin dose given to human volunteers was a single 100 mg dose. Intolerable anticholinergic side effects (fixed and dilated pupils, blurred vision, failure of heel-to-toe exam, tremors and dry skin) occurred on day 3 in normal volunteers taking 50 mg daily (5 times the maximum recommended therapeutic dose).
The absolute bioavailability of solifenacin is approximately 90%, and plasma concentrations of solifenacin are proportional to the dose administered.
The elimination half-life of solifenacin following chronic dosing is approximately 45-68 hours.
The primary pathway for elimination is by way of CYP3A4; however, alternate metabolic pathways exist.
* 600 L